Nasdaq:US$20.09 (-0.08) | HKEX:HK$31.50 (-0.55) | AIM:£3.24 (+0)
Search Result
Previous Article   |   Next Article
Announcements & Press Releases | 29 Oct 2022

NANETS 2022:An open-label, Phase 1b/2 study of surufatinib in combination with tislelizumab in patients with advanced neuroendocrine tumors